RA Drug May Help Treat Recalcitrant Eczema
Treatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
Treatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
The device connects to standard operating room suction and is designed to support faster, more controlled explantation without requiring additional capital equipment or specialized training.